Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Social and non-social autism symptoms and trait domains are genetically dissociable.

Warrier V, Toro R, Won H, Leblond CS, Cliquet F, Delorme R, De Witte W, Bralten J, Chakrabarti B, Børglum AD, Grove J, Poelmans G, Hinds DA, Bourgeron T, Baron-Cohen S.

Commun Biol. 2019 Sep 3;2:328. doi: 10.1038/s42003-019-0558-4. eCollection 2019.

2.

RICOPILI: Rapid Imputation for COnsortias PIpeLIne.

Lam M, Awasthi S, Watson HJ, Goldstein J, Panagiotaropoulou G, Trubetskoy V, Karlsson R, Frei O, Fan CC, De Witte W, Mota NR, Mullins N, Brügger K, Lee H, Wray N, Skarabis N, Huang H, Neale B, Daly M, Mattheissen M, Walters R, Ripke S.

Bioinformatics. 2019 Aug 8. pii: btz633. doi: 10.1093/bioinformatics/btz633. [Epub ahead of print]

PMID:
31393554
3.

The implications of target saturation for the use of drug-target residence time.

de Witte WEA, Danhof M, van der Graaf PH, de Lange ECM.

Nat Rev Drug Discov. 2018 Dec 28;18(1):82-84. doi: 10.1038/nrd.2018.234. No abstract available.

PMID:
30591716
4.

Correction to: Modelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment models.

de Witte WEA, Rottschäfer V, Danhof M, van der Graaf PH, Peletier LA, de Lange ECM.

J Pharmacokinet Pharmacodyn. 2018 Oct;45(5):763. doi: 10.1007/s10928-018-9604-y.

5.

In vitro and in silico analysis of the effects of D2 receptor antagonist target binding kinetics on the cellular response to fluctuating dopamine concentrations.

de Witte WEA, Versfelt JW, Kuzikov M, Rolland S, Georgi V, Gribbon P, Gul S, Huntjens D, van der Graaf PH, Danhof M, Fernández-Montalván A, Witt G, de Lange ECM.

Br J Pharmacol. 2018 Nov;175(21):4121-4136. doi: 10.1111/bph.14456. Epub 2018 Sep 21.

6.

Modelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment models.

de Witte WEA, Rottschäfer V, Danhof M, van der Graaf PH, Peletier LA, de Lange ECM.

J Pharmacokinet Pharmacodyn. 2018 Aug;45(4):621-635. doi: 10.1007/s10928-018-9593-x. Epub 2018 May 18. Erratum in: J Pharmacokinet Pharmacodyn. 2018 Aug 31;:.

7.

Target and Tissue Selectivity Prediction by Integrated Mechanistic Pharmacokinetic-Target Binding and Quantitative Structure Activity Modeling.

Vlot AHC, de Witte WEA, Danhof M, van der Graaf PH, van Westen GJP, de Lange ECM.

AAPS J. 2017 Dec 4;20(1):11. doi: 10.1208/s12248-017-0172-7.

PMID:
29204742
8.

From receptor binding kinetics to signal transduction; a missing link in predicting in vivo drug-action.

Nederpelt I, Kuzikov M, de Witte WEA, Schnider P, Tuijt B, Gul S, IJzerman AP, de Lange ECM, Heitman LH.

Sci Rep. 2017 Oct 26;7(1):14169. doi: 10.1038/s41598-017-14257-4.

9.

Novel CNS drug discovery and development approach: model-based integration to predict neuro-pharmacokinetics and pharmacodynamics.

de Lange ECM, van den Brink W, Yamamoto Y, de Witte WEA, Wong YC.

Expert Opin Drug Discov. 2017 Dec;12(12):1207-1218. doi: 10.1080/17460441.2017.1380623. Epub 2017 Sep 21. Review.

PMID:
28933618
10.

The influence of drug distribution and drug-target binding on target occupancy: The rate-limiting step approximation.

de Witte WEA, Vauquelin G, van der Graaf PH, de Lange ECM.

Eur J Pharm Sci. 2017 Nov 15;109S:S83-S89. doi: 10.1016/j.ejps.2017.05.024. Epub 2017 May 12.

11.

Kinetics for Drug Discovery: an industry-driven effort to target drug residence time.

Schuetz DA, de Witte WEA, Wong YC, Knasmueller B, Richter L, Kokh DB, Sadiq SK, Bosma R, Nederpelt I, Heitman LH, Segala E, Amaral M, Guo D, Andres D, Georgi V, Stoddart LA, Hill S, Cooke RM, De Graaf C, Leurs R, Frech M, Wade RC, de Lange ECM, IJzerman AP, Müller-Fahrnow A, Ecker GF.

Drug Discov Today. 2017 Jun;22(6):896-911. doi: 10.1016/j.drudis.2017.02.002. Epub 2017 Apr 13. Review.

PMID:
28412474
12.

A novel CCR2 antagonist inhibits atherogenesis in apoE deficient mice by achieving high receptor occupancy.

Bot I, Ortiz Zacarías NV, de Witte WE, de Vries H, van Santbrink PJ, van der Velden D, Kröner MJ, van der Berg DJ, Stamos D, de Lange EC, Kuiper J, IJzerman AP, Heitman LH.

Sci Rep. 2017 Mar 3;7(1):52. doi: 10.1038/s41598-017-00104-z.

13.

In vivo Target Residence Time and Kinetic Selectivity: The Association Rate Constant as Determinant.

de Witte WEA, Danhof M, van der Graaf PH, de Lange ECM.

Trends Pharmacol Sci. 2016 Oct;37(10):831-842. doi: 10.1016/j.tips.2016.06.008. Epub 2016 Jul 6. Review.

PMID:
27394919
14.

Assessment of Interspecies Differences in Drug-Induced QTc Interval Prolongation in Cynomolgus Monkeys, Dogs and Humans.

Dubois VF, de Witte WE, Visser SA, Danhof M, Della Pasqua O; Cardiovascular Safety Project Team; TI Pharma PKPD Platform.

Pharm Res. 2016 Jan;33(1):40-51. doi: 10.1007/s11095-015-1760-9. Epub 2015 Nov 9.

15.

Mechanistic models enable the rational use of in vitro drug-target binding kinetics for better drug effects in patients.

de Witte WE, Wong YC, Nederpelt I, Heitman LH, Danhof M, van der Graaf PH, Gilissen RA, de Lange EC.

Expert Opin Drug Discov. 2016;11(1):45-63. doi: 10.1517/17460441.2016.1100163. Epub 2015 Oct 20. Review.

PMID:
26484747
16.

Mannopyranosyl uronic acid donor reactivity.

Walvoort MT, de Witte W, van Dijk J, Dinkelaar J, Lodder G, Overkleeft HS, Codée JD, van der Marel GA.

Org Lett. 2011 Aug 19;13(16):4360-3. doi: 10.1021/ol2016862. Epub 2011 Jul 21.

PMID:
21776974

Supplemental Content

Loading ...
Support Center